NextEra Energy Targets Top End of 2026 Adjusted EPS Guidance of $3.92-$4.02
Bitget2026/11/09 14:06- NextEra Energy targets the top end of its 2026 adjusted EPS guidance range of $3.92-$4.02.
- Adjusted EPS is expected to grow at least 8% annually through 2032, with the same target through 2035, from $3.71 in 2025.
- The proposed Dominion Energy merger would lift targeted annual adjusted EPS growth above 9%; closing is expected in the second half of 2027.
- Year-to-date adjusted EPS rose 9.5%, while renewables and storage backlog additions reached 3.7 GW in the third quarter.
- Dividend growth is expected at approximately 10% annually through 2026 from a 2024 base, then 6% annually through 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
